Protalix BioTherapeutics, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-83.4M | $-29.4M | $58.0M | $-29.9M | $-27.8M | $-11.6M | $-36.5M | $-29.0M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $1.9M | $2.0M | $2.4M | $3.1M | $3.5M | $3.7M | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $337.0K | $988.0K | $1.8M | $1.2M | $4.1M | $7.8M | $886.0K | $1.3M |
| Net Cash from Operating Activities | $-10.0M | $-32.1M | $-24.3M | $-29.3M | $-30.7M | $635.0K | $-23.6M | $-38.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $971.0K | $849.0K | $464.0K | $785.0K | $1.9M | $2.1M | $5.7M | $7.9M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-1.1M | $-967.0K | $39.4M | $-1.0M | $-2.1M | $-2.3M | $-5.9M | $-8.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-1.4M | $19.7M | $6.6M | — | — | $26.6M | $20.9M | $501.0K |
| Net Change in Cash | $-12.1M | $-13.1M | $21.6M | $-31.6M | $34.4M | $25.0M | $-8.9M | $-45.4M |
| Free Cash Flow | $-11.0M | $-32.9M | $-24.7M | $-30.1M | $-32.5M | $-1.4M | $-29.3M | $-46.3M |